8-K: Teva's Innovative Portfolio Drives 11th Quarter Growth

Teva Pharmaceutical Industries reports strong Q3 2025 results, driven by innovative brands and an increased outlook for Austedo, despite some segment declines.

Summary

• Teva reported revenues of $4.5 billion in Q3 2025, a 3% increase year-over-year (YoY) in U.S. dollars, or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC.
• GAAP operating income margin was 19.7% and non-GAAP operating income margin reached 28.9% (+86 bps YoY), aligning with the Pivot to Growth Strategy's 30% non-GAAP operating profit margin target by 2027.
• Key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 33% YoY in LC, contributing $830 million in Q3 2025 revenues.
• AUSTEDO global revenues were $618 million (+38% LC YoY), leading to an increased 2025 revenue outlook by $50 million $100 million to a new range of $2,050 million $2,150 million.
• AJOVY global revenues were $168 million (+19% LC YoY), with its 2025 revenue outlook reaffirmed at $630 million $640 million.
• UZEDY revenues were $43 million (+24% YoY), with its 2025 revenue outlook reaffirmed at $190 million $200 million.
• The company launched liraglutide injection, the first-ever generic GLP-1 treatment for weight loss, strengthening its complex generics portfolio.
• Key pipeline milestones include positive Phase 3 SOLARIS data for olanzapine LAI (TEV-749) with NDA filing anticipated in Q4 2025, and FDA Fast Track designation for emrusolmin (TEV-286) for Multiple System Atrophy.
• Full-year 2025 outlook for revenues was tightened to $16.8 billion $17.0 billion, while non-GAAP operating income, adjusted EBITDA, and non-GAAP diluted EPS outlooks were increased at the low-end and mid-point.
• Cash flow generated from operating activities was $369 million in Q3 2025, down from $693 million in Q3 2024, mainly due to timing of sales and collections, as well as higher legal settlement payments.
• Free cash flow was $515 million in Q3 2025, down from $922 million in Q3 2024.
• Total debt decreased to $16,790 million as of September 30, 2025, from $17,783 million as of December 31, 2024.

Sentiment

Score: 7

Explanation: The filing indicates strong performance in key innovative brands, leading to increased guidance for profitability metrics and AUSTEDO revenue. The strategic 'Pivot to Growth' appears to be gaining traction. However, the termination of TAPI divestment discussions and a decrease in cash flow from operations and free cash flow temper the overall positive sentiment.

Positives

• 11th consecutive quarter of growth, demonstrating accelerating momentum of transformation and strength of innovation-led strategy.
• Key innovative brands revenue increased 33% YoY in local currency to $830 million.
• AUSTEDO global revenues grew 38% in local currency YoY to $618 million, with U.S. revenue up 38% YoY.
• AUSTEDO 2025 revenue outlook increased by $50 million $100 million to a new range of $2,050 million $2,150 million.
• AUSTEDO is on track for its 2027 revenue target of >$2.5 billion and peak year revenue target of >$3 billion.
• AJOVY global revenues increased 19% in local currency YoY to $168 million.
• UZEDY revenues increased 24% YoY to $43 million.
• Launch of liraglutide injection, the first-ever generic GLP-1 treatment for weight loss, strengthens the complex generics portfolio.
• Biosimilars strategic portfolio shows strong growth and is on track for 2027 expectations.
• Positive Phase 3 SOLARIS clinical trial data for olanzapine LAI (TEV-749) showing no PDSS cases, with NDA filing anticipated in Q4 2025.
• emrusolmin (TEV-286) received U.S. FDA Fast Track designation for Multiple System Atrophy.
• Phase 3 programs for duvakitug (anti-TL1A) in ulcerative colitis (UC) and Crohn's disease (CD) initiated by Sanofi and Teva in October 2025.
• Non-GAAP operating income margin increased by 86 bps YoY to 28.9%, on track for the 30% target by 2027.
• Teva Transformation programs are on track to deliver ~$700 million of net savings by 2027.
• GAAP diluted EPS improved significantly to $0.37 in Q3 2025 from a loss of $0.39 in Q3 2024.
• Non-GAAP diluted EPS increased to $0.78 in Q3 2025 from $0.69 in Q3 2024.
• Total debt decreased to $16,790 million as of September 30, 2025, from $17,783 million as of December 31, 2024.

Negatives

• Europe segment revenues decreased by 10% in local currency YoY, mainly due to higher proceeds from product rights sales in Q3 2024 and lower generic product revenues.
• International Markets segment revenues decreased by 10% in local currency YoY, mainly due to the divestment of the Japan business venture.
• Cash flow generated from operating activities decreased to $369 million in Q3 2025 from $693 million in Q3 2024, mainly due to timing of sales and collections, and higher legal settlement payments.
• Free cash flow decreased to $515 million in Q3 2025 from $922 million in Q3 2024.
• Exclusive discussions for the sale of the TAPI business have terminated, requiring Teva to initiate a renewed sales process, creating uncertainty regarding timing and completion.
• Revenues from other activities (primarily API sales to third parties and contract manufacturing) decreased by 10% in U.S. dollars, or 13% in local currency terms, compared to Q3 2024.

Risks

• Substantial dependence on generic products and intense competition from other pharmaceutical companies.
• Concentration of customer base and commercial alliances among customers.
• Delays in launches of new generic products and ability to develop and commercialize additional pharmaceutical products.
• Competition for innovative medicines and ability to achieve expected results from product pipeline investments.
• Ability to successfully execute the Pivot to Growth strategy, including expanding innovative and biosimilar medicines pipeline, profitably commercializing the portfolio, sustaining and focusing generics, and achieving organizational transformation and cost savings.
• Effectiveness of patents and other measures to protect intellectual property rights, including potential challenges to Orange Book patent listings.
• Significant indebtedness may limit ability to incur additional debt, engage in transactions, or make new investments.
• Potential need to raise additional funds in the future, which may not be available on acceptable terms or at all.
• Impact of global economic conditions, macroeconomic developments, and governmental/societal responses.
• Widespread outbreak of illness or any other communicable disease, or public health crisis.
• Effectiveness of optimization efforts and significant disruptions of information technology systems, including cybersecurity attacks and data breaches.
• Interruptions in supply chain or problems with internal or third-party manufacturing.
• Any impact of a prolonged government shutdown.
• Challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism (e.g., Russia/Ukraine, Middle East conflicts).
• Ability to attract, hire, integrate, and retain highly skilled personnel.
• Ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions.
• Prospects and opportunities for growth if assets or business units are sold, and ability to successfully and cost-effectively consummate such sales and divestitures, including the planned divestiture of the API business.
• Failure to comply with complex legal and regulatory requirements and changes.
• Effects of governmental and civil proceedings and litigation (e.g., opioid medications, generic drug antitrust litigation).
• Effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement, and coverage, including as a result of the One Big Beautiful Bill (OBBBA) and U.S. Executive Orders.
• Increased legal and regulatory action in connection with public concern over opioid abuse.
• Ability to timely make payments required under nationwide opioid settlement agreement and provide generic Narcan.
• Scrutiny from competition and pricing authorities, including compliance with deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ).
• Potential liability for intellectual property right infringement and product liability claims.
• Failure to comply with complex Medicare, Medicaid, and other governmental programs reporting and payment obligations.
• Compliance with sanctions and trade control laws and environmental risks.
• Impact of sustainability issues.
• Exposure to currency fluctuations and restrictions, as well as credit risks.
• Potential impairments of long-lived assets.
• Potential significant increases in tax liabilities and the effect on overall effective tax rate of program/benefit termination or business changes.
• Exposure to changes in international trade policies, including tariffs, and their effects on sales, pricing, and raw material availability.
• Impact of any future failure to establish and maintain effective internal control over financial reporting.

Future Outlook

Teva is on track to achieve its non-GAAP operating profit margin target of 30% by 2027 and ~$700 million of net savings from its Transformation programs. The company increased its 2025 revenue outlook for AUSTEDO to $2,050 million $2,150 million, with long-term targets of >$2.5 billion by 2027 and >$3 billion peak year revenue, reinforced by IRA price-setting. Outlooks for AJOVY and UZEDY were reaffirmed. The NDA filing for olanzapine LAI is anticipated in Q4 2025, and target enrollment for DARIs Phase 3 trial is expected by the end of 2025. The company will initiate a renewed sales process for its API business following the termination of exclusive discussions.

Management Comments

• "Our innovative portfolio driving the 11th consecutive quarter of growth in the third quarter reflects the accelerating momentum of our transformation and the strength of our innovation-led Pivot to Growth strategy."
• "Our key growth drivers—particularly our innovative medicines—delivered a 33% increase in local currency, underscoring their impact on both patient outcomes and our financial performance."
• "As we continue executing our strategy, we remain firmly on track to reach our 30% non-GAAP operating profit margin by 2027 and ~$700 million of net savings target."
• "Following the conclusion of the IRA pricing negotiations, we are reiterating our strong confidence in our AUSTEDO 2027 target."
• "Our differentiated innovative portfolio is now a defining strength for Teva as we transform into a leading innovative biopharma, while our world-class generics business continues to provide a resilient foundation."
• "With our talented team and unwavering commitment to patients, we are confident about Teva's future and our ability to deliver enduring value to all our stakeholders."

Industry Context

Teva's continued growth in innovative brands like AUSTEDO, AJOVY, and UZEDY positions it favorably in the specialty pharmaceutical market, aligning with a broader industry trend towards higher-value, differentiated products. The launch of the first generic GLP-1 treatment for weight loss (liraglutide injection) taps into a rapidly expanding and highly competitive market segment, demonstrating Teva's ability to leverage its generics expertise in high-demand areas. The FDA Fast Track designation for emrusolmin for Multiple System Atrophy highlights the ongoing industry focus on addressing unmet medical needs in rare neurodegenerative diseases. The impact of the Inflation Reduction Act (IRA) on drug pricing, specifically for AUSTEDO, reflects the increasing regulatory pressure on pharmaceutical pricing in the U.S., which companies must navigate for long-term revenue stability.

Comparison to Industry Standards

• The launch of liraglutide injection (generic Saxenda) positions Teva as the first to market with a generic GLP-1 treatment for weight loss. This is a significant competitive advantage in a market dominated by branded GLP-1 agonists like Novo Nordisk's Wegovy/Ozempic and Eli Lilly's Zepbound/Mounjaro, which have seen explosive growth. Being first to market with a generic in this high-demand category could allow Teva to capture substantial market share before other generic competitors emerge.
• AUSTEDO's projected 2027 revenue target of >$2.5 billion and peak year revenue target of >$3 billion, despite IRA price-setting, indicates strong confidence in its market position for tardive dyskinesia and Huntington's disease. This suggests a robust competitive moat and continued demand, potentially outperforming some other specialty drugs facing more aggressive generic erosion or therapeutic competition.
• The 30% non-GAAP operating profit margin target by 2027, driven by the 'Pivot to Growth' strategy and transformation programs, aims to bring Teva's profitability closer to leading innovative biopharma companies, which often achieve higher margins than pure-play generic manufacturers. This strategic shift is critical for long-term value creation, moving away from the lower-margin, high-volume generics business that has historically pressured Teva.

Legal Proceedings

• Legal settlements and loss contingencies of $60 million in Q3 2025, mainly an update to the estimated settlement provision for opioid cases ($42 million).
• In Q3 2024, legal settlements and loss contingencies included a $350 million provision for an EU antitrust investigation into COPAXONE and a $121 million update for opioid cases.
• For the nine months ended September 30, 2025, adjustments for legal settlements and loss contingencies included $139 million for opioid cases and $55 million for generic drug antitrust litigation.

Stakeholder Impact

• **Shareholders:** Positive impact from increased non-GAAP EPS outlook, strong innovative brand growth, and debt reduction. Uncertainty from TAPI divestment delay could cause short-term volatility.
• **Employees:** Teva Transformation programs include optimization activities, primarily through headcount reduction, which may impact employees.
• **Customers:** Expanded access to effective weight management options with the launch of generic GLP-1 treatment. Continued availability of innovative medicines for neurological conditions.
• **Suppliers:** Potential impact from supply chain optimization efforts and the divestment of the API business.
• **Creditors:** Positive impact from significant debt reduction and improved profitability outlook, enhancing creditworthiness.

Next Steps

• Anticipate filing of New Drug Application (NDA) for olanzapine LAI (TEV-749) in Q4 2025.
• Target enrollment levels for DARIs (Dual-action Asthma Rescue Inhaler) Phase 3 trial by the end of 2025.
• Initiate a renewed sales process for the API business following the termination of exclusive discussions.
• Continue executing the four key pillars of the Pivot to Growth strategy, focusing on growing the innovative portfolio, aligning capital allocation, and modernizing operations.
• CMS expected to announce the agreement on AUSTEDO maximum fair price in November 2025, with revised prices effective January 1, 2027.

Key Dates

Recommendation

Teva's Q3 2025 results show strong momentum in its innovative portfolio, particularly AUSTEDO, leading to an upward revision of its full-year non-GAAP operating income, EBITDA, and EPS guidance. The 'Pivot to Growth' strategy is yielding positive results, and debt reduction is a favorable sign. However, the termination of exclusive discussions for the TAPI divestment introduces uncertainty and potential delays in a key strategic initiative. While the core business performance is improving, the TAPI divestment issue and the decline in operating and free cash flow for the quarter suggest a 'hold' recommendation. Investors should monitor the renewed TAPI sales process and continued cash flow generation before considering a stronger position.

Keywords

Pharmaceuticals, Biopharma, Generics, Innovative Medicines, AUSTEDO, AJOVY, UZEDY, SEC Filing, Financial Results, Q3 2025, Teva, Drug Development, Neuroscience, Immunology, Biosimilars, GLP-1, Weight Loss, Tardive Dyskinesia, Huntington's Disease, Migraine, Schizophrenia, Multiple System Atrophy, API Divestment, Pivot to Growth Strategy, Earnings, Outlook